1. Home
  2. KRYS vs TFSL Comparison

KRYS vs TFSL Comparison

Compare KRYS & TFSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KRYS
  • TFSL
  • Stock Information
  • Founded
  • KRYS 2015
  • TFSL 1938
  • Country
  • KRYS United States
  • TFSL United States
  • Employees
  • KRYS N/A
  • TFSL N/A
  • Industry
  • KRYS Biotechnology: Biological Products (No Diagnostic Substances)
  • TFSL Savings Institutions
  • Sector
  • KRYS Health Care
  • TFSL Finance
  • Exchange
  • KRYS Nasdaq
  • TFSL Nasdaq
  • Market Cap
  • KRYS 3.6B
  • TFSL 3.7B
  • IPO Year
  • KRYS 2017
  • TFSL 2007
  • Fundamental
  • Price
  • KRYS $133.05
  • TFSL $12.68
  • Analyst Decision
  • KRYS Strong Buy
  • TFSL Hold
  • Analyst Count
  • KRYS 8
  • TFSL 1
  • Target Price
  • KRYS $211.13
  • TFSL $15.00
  • AVG Volume (30 Days)
  • KRYS 320.8K
  • TFSL 282.0K
  • Earning Date
  • KRYS 08-04-2025
  • TFSL 07-29-2025
  • Dividend Yield
  • KRYS N/A
  • TFSL 8.95%
  • EPS Growth
  • KRYS 109.01
  • TFSL 0.98
  • EPS
  • KRYS 4.16
  • TFSL 0.28
  • Revenue
  • KRYS $333,448,000.00
  • TFSL $304,101,000.00
  • Revenue This Year
  • KRYS $44.05
  • TFSL $0.93
  • Revenue Next Year
  • KRYS $46.15
  • TFSL $4.05
  • P/E Ratio
  • KRYS $31.77
  • TFSL $45.07
  • Revenue Growth
  • KRYS 247.53
  • TFSL 0.00
  • 52 Week Low
  • KRYS $122.80
  • TFSL $11.29
  • 52 Week High
  • KRYS $219.34
  • TFSL $15.00
  • Technical
  • Relative Strength Index (RSI)
  • KRYS 44.16
  • TFSL 37.08
  • Support Level
  • KRYS $127.99
  • TFSL $12.54
  • Resistance Level
  • KRYS $143.20
  • TFSL $13.42
  • Average True Range (ATR)
  • KRYS 4.23
  • TFSL 0.21
  • MACD
  • KRYS 1.01
  • TFSL -0.08
  • Stochastic Oscillator
  • KRYS 44.48
  • TFSL 15.91

About KRYS Krystal Biotech Inc.

Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.

About TFSL TFS Financial Corporation

TFS Financial Corp is the holding company for the Third Federal Savings and Loan Association of Cleveland. The company's ownership in the savings and loan association is its primary business activity. The association's principal business consists of originating and servicing residential real estate mortgage loans and attracting retail savings deposits. It does so by offering products with competitive rates and yields. The company also operates Third Capital, a wholly owned subsidiary that serves as a holding company or as an investor in vehicles such as private equity funds. Third Capital has interests in lease transactions of commercial buildings, title agencies providing escrow and settlement services, and reinsurance of private mortgage insurance on residential loans.

Share on Social Networks: